

AMENDMENTS TO THE CLAIMS

1. (currently amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
 - (a) the nucleotide sequence as set forth in any of SEQ ID NO: 1 **and or** SEQ ID NO: 3;
 - (b) a nucleotide sequence encoding a the polypeptide at least 85% identical to one of:
 - the polypeptide as set forth in any of SEQ ID NO: 2, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2; or
 - the polypeptide as set forth in SEQ ID NO: 4, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 4; and
 - (c) a nucleotide sequence which hybridizes under **moderately** stringent conditions with one of:
 - (a) or (b); or
 - the nucleotide sequence 1-102 of SEQ ID NO: 1 or 1-102 of SEQ ID NO: 3; or
 - the nucleotide sequence 319-606 of SEQ ID NO: 1 or 319-606 of SEQ ID NO: 3; or
 - the nucleotide sequence 1027-1201 of SEQ ID NO: 3[[..]]; or
 - a nucleotide sequence encoding a polypeptide as set forth in any of SEQ ID NO: 2 or SEQ ID NO: 4, with one conservative amino acid substitution, wherein the encoded polypeptide has an activity of the polypeptide set forth in any of SEQ ID NO: 2 or SEQ ID NO: 4.
- 2.-3. (canceled)
4. (currently amended) A vector comprising the nucleic acid molecule of **any of claims 1, 2, or 3 claim 1 and a promoter operatively linked to the nucleic acid molecule.**
5. (original) A host cell comprising the vector of claim 4.
6. (original) The host cell of claim 5 that is a eukaryotic cell.
7. (original) The host cell of claim 5 that is a prokaryotic cell.

8. (original) A process of producing an LGR6-SVs polypeptide comprising culturing the host cell of claim 5 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

9. (currently amended) A polypeptide ~~produced by the process of claim 8 or~~ encoded by the nucleotide sequences of claim 1.

10. (currently amended) The process of claim 8, wherein the ~~nucleic acid molecule comprises is~~ promoter ~~is not DNA other than the native~~ promoter DNA for the native LGR6-SVs polypeptide ~~operatively linked to the DNA encoding the LGR6-SVs polypeptide.~~

11. (canceled)

12. (currently amended) A process for determining whether a compound inhibits LGR6-SVs polypeptide activity or LGR6-SVs polypeptide production comprising:

(a) exposing a cell according to ~~claim 5 any of claims 5, 6, or 7~~ to the compound; and

(b) measuring one of:

- LGR6-SVs polypeptide activity in said cell, wherein a decrease in activity indicates that the compound inhibits LGR6-SVs polypeptide activity; or
- LGR6-SVs polypeptide production in said cell, wherein a decrease in production indicates that the compound inhibits LGR6-SVs polypeptide production.

13. (currently amended) ~~The An isolated polypeptide comprising the amino-acid sequence as set forth in any of claim 9 wherein the polypeptide is characterized by the following:~~

(a) the polypeptide comprises the sequence set forth in SEQ ID NO: 2;

(b) the polypeptide comprises the sequence set forth in or SEQ ID NO: 4;

(c) the polypeptide comprises the sequence set forth in SEQ ID NO: 2 with one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2;

(d) the polypeptide comprises the sequence set forth in SEQ ID NO: 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in any of SEQ ID NO: 2 or SEQ ID NO: 4.

14. (currently amended) The A-mature form of the isolated polypeptide according to claim 13, wherein the polypeptide does not comprise a signal sequence.
15. (currently amended) An antibody A-selective binding agent or fragment thereof that specifically binds the polypeptide of any of claim 13 claims 13 or 14.
16. (currently amended) The antibody selective binding agent or fragment thereof of claim 15 wherein the antibody that specifically binds a the polypeptide comprising the amino acid sequence as set forth in any of SEQ ID NO: 2 or SEQ ID NO: 4 or a fragment thereof.
17. (currently amended) The antibody selective binding agent of claim 16 wherein the that is an antibody comprises a Fab or F(ab') or a fragment thereof.
18. (currently amended) The antibody selective binding agent of claim 17 wherein the antibody that is a humanized antibody.
19. (currently amended) A method for treating, preventing, or ameliorating an LGR6-SVs polypeptide-related disease, condition, or disorder comprising administering to a patient an ~~effective amount of a selective binding agent antibody~~ according to claim 16.
- 20.-22 (canceled)
23. (currently amended) A composition comprising the polypeptide of claim 13 any of claims 13 or 14 and a pharmaceutically acceptable formulation agent.
- 24.-26. (canceled)
27. (currently amended) The polypeptide of claim 13 or 14 that wherein the polypeptide is covalently modified with a water-soluble polymer selected from the group consisting of polyethylene glycol, mono-methoxy polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide copolymers, polyoxyethylated polyols, and polyvinyl alcohol.
- 28.-31. (canceled)
32. (currently amended) The A-fusion polypeptide of claim 13 wherein comprising the polypeptide of any of claims 13 or 14 fused to a heterologous amino-acid sequencee is a fusion protein.

33. (currently amended) The fusion polypeptide of claim 32, wherein the **fusion protein comprises heterologous amino acid sequence** is an IgG constant domain or fragment thereof.

34. (canceled)